| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Zinpyr-1 selectively binds to zinc ions and emits fluorescence upon binding. The mechanism of action involves the displacement of water molecules from the zinc ion, followed by the coordination of the nitrogen atoms of the ligand to the zinc ion. This fluorescence turn-on response enables the detection and imaging of zinc ions in biological systems. The compound does not have a pharmacological target but serves as a research tool for zinc imaging.
|
|---|---|
| ln Vitro |
In vitro, Zinpyr-1 is used as a fluorescent probe for the detection and imaging of zinc ions in biological samples. It is cell-permeable and selectively binds to zinc ions, emitting fluorescence upon binding with an emission maximum of 527 nm. The compound is widely used in cell biology research to study zinc homeostasis, zinc signaling, and the role of zinc in various cellular processes.
|
| ln Vivo |
In vivo, Zinpyr-1 has been used for imaging zinc ions in living organisms. The compound's cell permeability and selectivity for zinc make it useful for studying zinc distribution and dynamics in tissues. Specific in vivo pharmacokinetic and pharmacodynamic data for the compound as a drug are not available, as it is a research probe rather than a therapeutic agent.
|
| Enzyme Assay |
For in vitro fluorescence imaging experiments, Zinpyr-1 is used as a zinc-specific fluorescent probe. Standard protocols involve dissolving the compound in DMSO to prepare a stock solution and adding it to cells or tissue samples at appropriate concentrations (typically 1-10 µM). Cells are incubated with the probe for 30-60 minutes at 37°C, washed, and then imaged using fluorescence microscopy with excitation/emission settings appropriate for fluorescein-based probes.
|
| Cell Assay |
For in vitro cell-based experiments, Zinpyr-1 is used to monitor intracellular zinc levels. Cells are incubated with the probe and fluorescence intensity is measured using a fluorescence plate reader or flow cytometry. Changes in fluorescence intensity in response to zinc chelators, zinc ionophores, or other treatments are used to assess zinc homeostasis and signaling. The compound's selectivity for zinc over other metal ions has been characterized.
|
| Animal Protocol |
In vivo animal studies using Zinpyr-1 are conducted for zinc imaging applications. The probe is administered to rodents via intravenous injection or local administration, and zinc distribution and dynamics are visualized using fluorescence imaging techniques. Standard in vivo protocols involve administration of the probe, allowing time for distribution, and then performing imaging studies to detect zinc signals in tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Zinpyr-1 are not available, as the compound is a fluorescent probe used for research applications rather than a drug candidate. The compound has a molecular weight of 823.72 g/mol. As a large, polar molecule, it may have limited membrane permeability despite being described as cell-permeable. The compound is primarily used as a research tool rather than as a drug candidate.
|
| Toxicity/Toxicokinetics |
Zinpyr-1 is a research chemical and should be handled with appropriate laboratory safety precautions. As a fluorescent probe, it may cause skin and eye irritation. The compound should be stored under appropriate conditions. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a well-ventilated area.
|
| Additional Infomation |
bright fluorescent divalent zinc sensor based on fluorescein; structure described in the first reference.
Zinpyr-1 (CAS 288574-78-7) is primarily a research-grade fluorescent probe, not an FDA-approved pharmaceutical drug. Its primary application is as a cell-permeable fluorescent probe with selectivity for zinc ions, used for imaging and studying zinc in biological systems. No clinical trials or approved therapeutic indications exist for this compound. |
| Molecular Formula |
C46H36CL2N6O5
|
|---|---|
| Molecular Weight |
823.72
|
| Exact Mass |
822.212
|
| CAS # |
288574-78-7
|
| PubChem CID |
58780151
|
| Appearance |
Orange to red solid powder
|
| Density |
1.49g/cm3
|
| Boiling Point |
931.2±65.0 °C at 760 mmHg
|
| Melting Point |
185-187ºC
|
| Flash Point |
517.0±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.745
|
| LogP |
6.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
59
|
| Complexity |
1270
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)Cl)O)CN(CC6=CC=CC=N6)CC7=CC=CC=N7)CN(CC8=CC=CC=N8)CC9=CC=CC=N9)O)Cl
|
| InChi Key |
QZKKSPLNXQJQRQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C46H36Cl2N6O5/c47-39-21-37-43(34(41(39)55)27-53(23-29-11-3-7-17-49-29)24-30-12-4-8-18-50-30)58-44-35(28-54(25-31-13-5-9-19-51-31)26-32-14-6-10-20-52-32)42(56)40(48)22-38(44)46(37)36-16-2-1-15-33(36)45(57)59-46/h1-22,55-56H,23-28H2
|
| Chemical Name |
4',5'-bis[[bis(pyridin-2-ylmethyl)amino]methyl]-2',7'-dichloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: < 0.1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2140 mL | 6.0700 mL | 12.1400 mL | |
| 5 mM | 0.2428 mL | 1.2140 mL | 2.4280 mL | |
| 10 mM | 0.1214 mL | 0.6070 mL | 1.2140 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
